Search the Newsreel

ResMed (RMD) investor Michael Farrell plans 4,991-share stock sale after option exercise

ResMed (RMD) investor Michael Farrell has filed a Form 144 indicating a proposed sale of 4,991 shares of common stock on August 7, 2026, following a stock option exercise. The shares are intended to be sold for cash via Fidelity Brokerage Services LLC on …

RBC Capital Adjusts PT on ResMed to $244 From $234, Maintains Sector Perform Rating

RBC Capital has increased its price target for ResMed (RMD) to $244 from $234, while maintaining a Sector Perform rating on the stock. This adjustment comes shortly after ResMed reported its fiscal Q4 non-GAAP earnings and revenue were up, though shares initially fell.

Trade Desk Posts Downbeat Q2 Results, Joins Sezzle, Resmed, Ouster And Other Big Stocks Moving Lower In Friday’s Pre-Market Session

The Trade Desk (NASDAQ: TTD) reported weaker-than-expected Q2 financial results, with earnings per share missing estimates by 15% and revenue falling short of Street estimates. This news caused Trade Desk shares to drop significantly in pre-market trading, impacting other stocks such as Sezzle, Quidelortho, …

Resmed Reports Strong Q4 Results and Dividend Increase

Resmed (RMD) reported strong Q4 and full-year fiscal 2026 results, with revenue up 9% and 10% respectively, and a 17% increase in non-GAAP diluted EPS. The company generated significant free cash flow, returned $1.0 billion to shareholders, and raised its quarterly dividend by 10% …

ResMed Inc (RMD) (Q4 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ...

ResMed Inc. reported strong Q4 FY2026 results with a 9% headline revenue growth and a 16% increase in non-GAAP EPS, achieving 10% revenue growth and $1.6 billion in free cash flow for the full fiscal year. The company plans to return over $1.85 billion …

ResMed beats on earnings and ups dividend, yet shares plummet

Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026

Resmed Inc. (NYSE: RMD, ASX: RMD) announced strong results for its fourth quarter and full fiscal year 2026, with Q4 revenue up 9% to a record $1.5 billion and non-GAAP diluted earnings per share increasing 16% to $2.95. The company returned $1.0 billion to …

ResMed Fiscal Q4 Non-GAAP Earnings, Revenue Up

ResMed reported increased non-GAAP earnings and revenue for its fiscal fourth quarter. The company's financial performance demonstrates growth during this period.

ResMed Introduced Guidance at Request of Investors, CEO Says

ResMed's CEO, Mick Farrell, explained that the company reintroduced financial guidance due to investor requests for more transparency regarding its growth prospects and market leadership. The decision comes after the company had previously paused guidance during the COVID-19 pandemic. This move aims to provide …

ResMed Inc. 2026 Q4 - Results - Earnings Call Presentation (NYSE:RMD) 2026-08-06

ResMed (NYSE:RMD) Posts Q2 CY2026 Sales In Line With Estimates But Stock Drops

ResMed (RMD) Q4 Earnings and Revenues Top Estimates

Earnings Flash (RMD) Resmed Inc. Posts Q4 Adjusted EPS $2.95 per Share, vs. FactSet Est of $2.89

Resmed Inc. (RMD) reported Q4 adjusted EPS of $2.95, surpassing the FactSet estimate of $2.89. The company's fiscal Q4 revenue was $1.46 billion, matching FactSet's estimate. Despite the positive earnings and revenue growth, ResMed's shares fell by 5%, indicating a perceived slowdown in growth.

Earnings Flash (RMD) Resmed Inc. Reports Q4 Revenue $1.46B, vs. FactSet Est of $1.46B

Resmed Inc. (RMD) reported its Q4 revenue at $1.46 billion, which matched the FactSet estimate. This financial update indicates the company's performance aligned with market expectations for the quarter. The news was released by MT Newswires.

Peter Farrell Sells 8,000 Shares of ResMed (NYSE:RMD) Stock

ResMed director Peter Farrell sold 8,000 shares of the company's stock for $1.8 million, reducing his holdings by 13.16% to 52,773 shares. The transaction, conducted under a Rule 10b5-1 trading plan, occurred on August 5th. ResMed's stock saw a slight increase of 0.1% to …

Resmed raises quarterly dividend 10% to $0.66 per share

Resmed reported strong Q4 FY2026 results with record revenue of $1.46 billion, up 9%, and non-GAAP EPS up 16%. For the full year FY2026, revenue increased 10% to $5.65 billion, with non-GAAP diluted EPS growing 17% to $11.17. The company also announced a 10% …

ResMed Inc. (NYSE: RMD) grows FY 2026 revenue to $5,653M and lifts dividend

ResMed Inc. reported strong financial results for fiscal year 2026 and the fourth quarter, with annual revenue increasing 10% to $5,653 million and non-GAAP diluted EPS rising 17% to $11.17. The company also announced a 10% increase in its quarterly cash dividend to $0.66 …

Resmed director Peter C. Farrell sells $1.8m in stock By Investing.com

ResMed director Peter C. Farrell sold 8,000 shares of company common stock for $1.8 million on August 5, 2026, under a Rule 10b5-1 trading plan. This transaction leaves him with 52,773 shares directly held. The sale occurred as ResMed's stock has declined by approximately …

ResMed (RMD) Faces An Earnings Test After A Rebound That Still Looks Undervalued

ResMed (RMD) is approaching its next earnings report with Wall Street anticipating $2.90 per share and $1.46 billion in revenue. Despite recent share price gains, the stock remains undervalued according to the most popular narrative, which sets a fair value of $247.93 compared to …

Form 144 ResMed INC For: 6 August By Investing.com

This article announces the filing of Form 144 for ResMed INC on August 6. Form 144 indicates an intent to sell restricted securities. The brief article, published by Investing.com, provides no further details beyond the filing announcement.

Does Higher EPS Guidance In Sleep And Breathing Health Shift The Bull Case For ResMed (RMD)?

Lazard Asset Management LLC Has $734,000 Stock Position in ResMed Inc. $RMD

Lazard Asset Management LLC significantly reduced its stake in ResMed Inc. by 68% in the first quarter, selling 6,948 shares but retaining 3,272 shares valued at approximately $734,000. Institutional investors now collectively own 54.98% of ResMed. The article also notes recent insider selling by …

ResMed (RMD) Earnings Date and Reports 2026 $RMD

Curious about ResMed (RMD) Q4 Performance? Explore Wall Street Estimates for Key Metrics

Wall Street analysts project that ResMed (RMD) will report Q4 earnings of $2.90 per share, an increase of 13.7% year-over-year, with revenues expected to reach $1.46 billion, up 8.4%. The consensus EPS estimate has seen a slight downward revision of 0.1% over the last …

ResMed (RMD) Q2 Earnings: What To Expect

Resmed Inc (RMD) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

ResMed Inc (RMD) Stock Up 3.7% and Still Undervalued -- GF Score: 90/100

ResMed Inc (RMD) saw its stock price increase by 3.7% to $223.14, and GuruFocus's GF Value™ assessment indicates it is currently undervalued with a fair value of $274.67. The company boasts a strong GF Score™ of 90/100, driven by excellent profitability and growth, though …

ResMed Inc. stock rises Tuesday, outperforms market

Shares of ResMed Inc. (RMD) rose 3.69% on Tuesday, closing at $223.14. This performance outpaced the broader market, with the S&P 500 Index (SPX) gaining 1.79% and the Dow Jones Industrial Average (DJIA) rising 1.71%. This marks the third consecutive day of gains for …

Confluence Investment Management LLC Has $18.34 Million Stock Position in ResMed Inc. $RMD

Confluence Investment Management LLC reduced its stake in ResMed Inc. (NYSE:RMD) by 5.8% in Q2, now holding 94,086 shares valued at $18.34 million. Despite this reduction, institutional ownership remains significant at 54.98%, with other firms like AllianceBernstein increasing their positions. ResMed shares opened at …

Resmed's Q4 Earnings on Deck: What's in Store for the Stock?

Resmed (RMD) is scheduled to release its fourth-quarter fiscal 2026 results on August 6, with analysts projecting an 8.4% revenue increase to $1.46 billion and a 13.7% rise in EPS to $2.90. The company's Sleep and Breathing Health segment is expected to drive growth …

ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth

Wall Street anticipates earnings growth for ResMed (RMD) when it reports its results for the quarter ending June 2026, with analysts expecting a 13.7% year-over-year increase in earnings per share and an 8.4% rise in revenues. However, the Zacks Earnings ESP indicates a potential …

ResMed (RMD) Could Be 14% Undervalued On Its Sleep Health Growth Story

ResMed (RMD) has seen a recent rebound in its stock price, with some investors believing it is undervalued by approximately 14% based on its growth narrative in the sleep health market. Strategic investments and increased global awareness of sleep health issues are cited as …

BofA Securities Maintains ResMed(RMD.US) With Buy Rating, Maintains Target Price $320

BofA Securities has reiterated its Buy rating for ResMed (RMD.US) and maintained a target price of $320. This indicates a continued positive outlook from the firm regarding ResMed's stock performance.

Resmed Inc (RMD) Institutional Confidence

The article details ResMed Inc.'s institutional confidence score, which is currently 5.00, placing it 107th in its industry. Institutional shareholding increased by 3.69% quarter-over-quarter, with ETHSX being the largest holder. It also lists top institutional shareholders and their changes in holdings.

Resmed Inc (RMD) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Resmed Inc (RMD), noting its current valuation score of 8.67, which ranks 72 out of 199 in the Healthcare Equipment & Supplies industry. The P/E ratio for RMD is reported as 20.07, indicating it is below its …

Resmed Inc (RMD) Financial Health: Profitability & Balance Sheet Analysis

Resmed Inc (RMD) has a strong financial health score of 9.76, placing it first in the Healthcare Equipment & Supplies industry. The company reported a quarterly revenue of $1.43 billion, marking a 10.81% year-over-year increase, and net profit grew by 9.23% year-over-year. Key financial …